TP53 and central nervous system cancer: Two prior studies in glioma and melanoma similarly showed anti-oncogenic effects with inhibition of MDM4 with shRNA targeting MDM4 or with SAH-p53-8, a stapled p53 helix that binds to MDM4 to block its interaction with endogenous, wild-type p5343,44.